Veradermics ph. 3 win backs up its stellar stock performance
Veradermics ph. 3 win backs up its stellar stock performance
Veradermics
New Haven, CT-based dermatology biotech developing dissolvable microarray patches for pattern hair loss (androgenetic alopecia), with a clinical-stage lead candidate.
Company Info
Upcoming Milestones & Key Dates
2026-Q3
IPO
IPO follow-on offering expected
2026-Q4
clinical
Phase 2 VER-001 topline data read-out
Clinical Development Pipeline
VER-001 microarray patch
Target: Topical minoxidil via dissolvable microneedleVER-002
Target: DermatologyVER-003
Target: TBDRecent News
Veradermics keeps 'momentum going' as baldness drug helps women with hair loss
Veradermics reports female-pattern hair loss results for its oral minoxidil baldness drug.
Veradermics reports ph. 2 win in female pattern hair loss
Veradermics reports ph. 2 win in female pattern hair loss
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom (reported by BioSpace)
Leadership Team
Reid Waldman
Founder and Chief Executive Officer